Literature DB >> 16718785

Correlation between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models.

Qing-He Nie1, Ya-Fei Zhang, Yu-Mei Xie, Xin-Dong Luo, Bin Shao, Jun Li, Yong-Xing Zhou.   

Abstract

AIM: To evaluate serum TIMP-1 level and the correlation between TIMP-1 expression and liver fibrosis in immune-induced and CCL4-induced liver fibrosis models in rats.
METHODS: Immune-induced and CCL4-induced liver fibrosis models were established by dexamethasone (0.01 mg) and CCL4 respectively. Serum TIMP-1 level was detected with ELISA, while histopathological grade of liver biopsy was evaluated. Spearman rank-correlation test was used to analyse the difference of the correlation between the TIMP-1 expression and hepatic fibrosis in the two fibrosis models. Furthermore, in situ hybridization was used to determine the expression difference of TIMP-1 mRNA in the two models.
RESULTS: Positive correlation existed between serum TIMP-1 level of immune induced group and the histopathological stages of fibrosis liver of corresponding rats (Spearman rank-correlation test, r(s) = 0.812, P < 0.05), and the positive in situ hybridization signal of TIMP-1 mRNA was strong. In CCL4-induced liver fibrosis model, the correlation between the serum TIMP-1 level and the severity of hepatic fibrosis was not statistically significant(Spearman rank-correlation test, r(s) = 0.229, P > 0.05). And compared with immune-induced model, the positive in situ hybridization signal of TIMP-1 mRNA was weaker, while the expression variation was higher in hepatic fibrosis of the same severity.
CONCLUSION: The correlations between TIMP-1 expression and liver fibrosis in two rat liver fibrosis models are different. In immune-induced model, serum TIMP-1 level could reflect the severity of liver fibrosis, while in CCL4-induced model, the correlation between the serum TIMP-1 level and the severity of hepatic fibrosis was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16718785      PMCID: PMC4124379          DOI: 10.3748/wjg.v12.i19.3044

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

Review 1.  Rating fibrosis progression in chronic liver diseases.

Authors:  William M C Rosenberg
Journal:  J Hepatol       Date:  2003-03       Impact factor: 25.083

Review 2.  Regulation of matrix biology by matrix metalloproteinases.

Authors:  Joni D Mott; Zena Werb
Journal:  Curr Opin Cell Biol       Date:  2004-10       Impact factor: 8.382

3.  [Expression and significance of tissue inhibitors of metallproteinases-1 and -2 in serum and liver tissue of patients with liver cirrhosis].

Authors:  Q Nie; Y Zhou; Y Xie
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2001-07-10

Review 4.  Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model.

Authors:  Lutz W D Weber; Meinrad Boll; Andreas Stampfl
Journal:  Crit Rev Toxicol       Date:  2003       Impact factor: 5.635

5.  Methodologic research on TIMP-1, TIMP-2 detection as a new diagnostic index for hepatic fibrosis and its significance.

Authors:  Qing-He Nie; Yong-Qian Cheng; Yu-Mei Xie; Yong-Xing Zhou; Xian-Guang Bai; Yi-Zhan Cao
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

6.  [Serum TIMP-1 concentration in patients with chronic glomerulonephritis and the effect of losartan].

Authors:  Xun Tang
Journal:  Di Yi Jun Yi Da Xue Xue Bao       Date:  2003-09

7.  [The diagnostic value of eight serum indices for liver fibrosis].

Authors:  Wei-min Cai; Bin-bin Zhang; Hong-lei Weng; Zhong-rong Hu; Jun Lv; Min Zheng; Rong-hua Liu
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2004-04

8.  Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.

Authors:  Bin-Bin Zhang; Wei-Min Cai; Hong-Lei Weng; Zhong-Rong Hu; Jun Lu; Min Zheng; Rong-Hua Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

9.  Expression of TIMP-1 and TIMP-2 in rats with hepatic fibrosis.

Authors:  Qing-He Nie; Guo-Rong Duan; Xin-Dong Luo; Yu-Mei Xie; Hong Luo; Yong-Xing Zhou; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

10.  Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid.

Authors:  Vincent Leroy; Frederique Monier; Serge Bottari; Candice Trocme; Nathalie Sturm; Marie-Noëlle Hilleret; Francoise Morel; Jean-Pierre Zarski
Journal:  Am J Gastroenterol       Date:  2004-02       Impact factor: 10.864

View more
  9 in total

1.  TIMP-1 deficiency subverts cell-cycle dynamics in murine long-term HSCs.

Authors:  Lara Rossi; Aysegul V Ergen; Margaret A Goodell
Journal:  Blood       Date:  2011-04-26       Impact factor: 22.113

2.  Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis.

Authors:  Qing-He Nie; Chuan-Long Zhu; Ya-Fei Zhang; Jie Yang; Jiu-Cong Zhang; Ren-Tao Gao
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

Review 3.  Oxidative and nitrosative stress and fibrogenic response.

Authors:  R Urtasun; L Conde de la Rosa; N Nieto
Journal:  Clin Liver Dis       Date:  2008-11       Impact factor: 6.126

4.  Developing an in vitro screening assay platform for evaluation of antifibrotic drugs using precision-cut liver slices.

Authors:  Satish Kumar Sadasivan; Nethra Siddaraju; Khaiser Mehdi Khan; Balamuralikrishna Vasamsetti; Nimisha R Kumar; Vibha Haridas; Madhusudhan B Reddy; Somesh Baggavalli; Anup M Oommen; Raghavendra Pralhada Rao
Journal:  Fibrogenesis Tissue Repair       Date:  2014-12-16

5.  MiR-29a reduces TIMP-1 production by dermal fibroblasts via targeting TGF-β activated kinase 1 binding protein 1, implications for systemic sclerosis.

Authors:  Marzena Ciechomska; Steven O'Reilly; Monika Suwara; Katarzyna Bogunia-Kubik; Jacob M van Laar
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

6.  Administration of N-Acyl-Phosphatidylethanolamine Expressing Bacteria to Low Density Lipoprotein Receptor-/- Mice Improves Indices of Cardiometabolic Disease.

Authors:  Linda S May-Zhang; Zhongyi Chen; Noura S Dosoky; Patricia G Yancey; Kelli L Boyd; Alyssa H Hasty; MacRae F Linton; Sean S Davies
Journal:  Sci Rep       Date:  2019-01-23       Impact factor: 4.379

7.  Dose-Dependent Antifibrotic Effect of Chrysin on Regression of Liver Fibrosis: The Role in Extracellular Matrix Remodeling.

Authors:  Cornel Balta; Alina Ciceu; Hildegard Herman; Marcel Rosu; Oana Maria Boldura; Anca Hermenean
Journal:  Dose Response       Date:  2018-08-08       Impact factor: 2.658

8.  Association of novel markers of liver disease with neonatal liver disease in premature baboons, Papio sp.

Authors:  Laura M Keller; Stephanie Eighmy; Cun Li; Lauryn Winter; Jay Kerecman; Zachary Goodman; Naveen Mittal; Cynthia L Blanco
Journal:  PLoS One       Date:  2020-03-09       Impact factor: 3.240

9.  Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine.

Authors:  Bernadette M M Zwaans; Heinz E Nicolai; Michael B Chancellor; Laura E Lamb
Journal:  PLoS One       Date:  2020-10-29       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.